«Det var kjempespennende å være her på Sykehusapoteket i dag», sier en entusiastisk Michael B. Lukac. Han og medelev Suhad Khalouf går tredjeåret på apotekteknikk på Ullern videregående skole. Denne dagen har de hatt utplassering hos Sykehusapoteket på Radiumhospitalet og læringskurven har vært bratt.
Can radiopharmaceuticals against cancer become Norway’s Novo Nordisk?
Politicians agree that Norway needs more clinical studies in cancer but are at odds as to how to reach the goals.
Children affected by cancer stepped into real research labs this weekend, gaining hands-on experience with the science behind their treatment through the “Researcher for a Day” programme.
A new arena to accelerate the development of cancer care has been launched in Sweden, building momentum for the European Cancer Mission.
Thor Medical has finished building its AlphaOne facility and begun commissioning, staying on track to start production in the third quarter.
Get monthly news updates and invitations to events from our oncology cluster.
11 elever fra både andre og tredje klasse på Ullern videregående skole fikk være en hel dag hos det franske legemiddelselskapet Sanofis kontorer i Norge på Lysaker. Ungdommene fikk noen aha-opplevelser om hva det vil si å jobbe i et legemiddelselskap, hva slags regler det finnes på feltet og framtidige jobbmuligheter.
An innovative cancer treatment from Norway will be tested for the first time on patients with glioblastoma in the US.
A new collaboration aims to bridge the gap between regulatory approval and the real-world information that clinicians and health authorities need to make informed treatment decisions.
Thor Medical has entered an agreement with Node Pharma to supply isotopes.
A new governmental plan makes bold promises to attract clinical studies to Norway, but will it deliver?
The government wants to focus Siva's activities solely on real estate. This is presented as a technical reorganisation, but in reality it is a political choice about the role the state should play in the development of new industries. We cannot spend innovation capital and expect to become richer.
